Trending Topics in Gastroenterology | GastroAGI

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can also serve as a cell of origin. Understanding the molecular events that initiate this transformation is critical for developing targeted preventive and therapeutic strategies. Why was this study needed?: The cellular origin of ICC remains incompletely understood. Mechanisms driving hepatocyte transformation into ICC are poorly defined. ARID1A mutations are common in ICC, but their functional role in tumor initiation is unclear. Identifying early molecular events could reveal novel therapeutic targets for this highly aggressive cancer. Results: Using complementary mouse and cellular models, the investigators demonstrated that hepatocytes undergo marked hyperpolyploidization during the earliest stages of ICC development. This hyperpolyploid state promoted abnormal cell division, chromosomal instability, and malignant transformation. Mechanistically, ARID1A was identified as a key regulator that suppresses hyperpolyploidy by maintaining normal centrosomal and mitotic function. Loss of ARID1A disrupted mitotic integrity, accelerated hepatocyte hyperpolyploidization, and promoted ICC formation, establishing a direct mechanistic link between ARID1A deficiency and hepatocyte-derived cholangiocarcinogenesis. Clinical Impact: This study reshapes current understanding of ICC pathogenesis by demonstrating that mature hepatocytes can directly give rise to ICC through ARID1A-dependent genomic instability. The findings identify hyperpolyploidization as a potential early biomarker and therapeutic target, while highlighting ARID1A-deficient ICC as a biologically distinct subtype that may benefit from future precision medicine approaches targeting chromosomal instability or mitotic regulation. Bottom Line: ARID1A deficiency promotes hepatocyte hyperpolyploidization and chromosomal instability, driving the development of intrahepatic cholangiocarcinoma and providing new mechanistic insights into ICC initiation and potential therapeutic targets.

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91 signaling pathway in HSCs could halt fibrosis progression. Why was this study needed? • Liver fibrosis is the strongest predictor of liver-related mortality in MASH. • Hepatic stellate cells are the principal drivers of fibrosis. • Succinate accumulates during metabolic liver injury and activates HSCs through the GPR91 receptor. • The therapeutic potential of targeting GPR91 had not been confirmed in vivo. • Novel molecular targets are urgently needed to prevent fibrosis progression. Results: • Blocking GPR91 specifically in hepatic stellate cells markedly reduced liver fibrosis, collagen deposition, and fibrogenic activity in experimental MASH. • Succinate promoted hepatic stellate cell activation and survival, whereas GPR91 inhibition suppressed profibrotic signaling and enhanced HSC apoptosis. • These findings identify the succinate–GPR91 pathway as a key driver of MASH fibrosis and a promising therapeutic target for future antifibrotic therapies. Clinical Impact: This study identifies a novel metabolic signaling pathway linking succinate accumulation to hepatic stellate cell activation and fibrosis. Targeting GPR91 could represent a new class of antifibrotic therapy capable of slowing or preventing fibrosis progression in patients with MASH. Bottom Line: The succinate–GPR91 signaling pathway is a major driver of liver fibrosis in MASH. Blocking GPR91 effectively suppresses hepatic stellate cell activation and fibrosis, making it a promising target for next-generation antifibrotic therapies.

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP) zone, where lipogenic hepatocytes communicate with lipid-associated macrophages (LAMs) to promote inflammation and fibrosis. Why was this study needed? • The mechanisms driving progression from steatosis to MASH remain incompletely understood. • Liver zonation may influence disease progression, but its role has been poorly defined. • Lipid-associated macrophages (LAMs) are increasingly recognized as key mediators of fibrosis. • Novel molecular targets beyond current therapies are urgently needed. • Understanding cell-to-cell communication may enable precision therapies for MASH. Results: • THRSP-positive hepatocytes promoted MASH progression by producing palmitic acid and recruiting CD74-positive lipid-associated macrophages through MIF signaling, particularly within the periportal region. • This hepatocyte–macrophage crosstalk amplified hepatic inflammation, stellate cell activation, and fibrosis, identifying a key mechanism underlying disease progression. • A novel THRSP inhibitor (C6) significantly reduced inflammation and fibrosis in experimental MASH, highlighting THRSP as a promising therapeutic target. Clinical Impact: This study provides important insight into the spatial biology of MASH, demonstrating that fibrosis is driven by localized communication between metabolically active hepatocytes and inflammatory macrophages. Targeting the THRSP–MIF–CD74 signaling axis may offer a new precision approach to prevent fibrosis progression beyond current therapies such as resmetirom. Bottom Line: Periportal THRSP-positive hepatocytes orchestrate MASH progression by recruiting CD74-positive lipid-associated macrophages through MIF signaling. Interrupting this pathway with THRSP inhibition represents a promising new strategy for treating MASH-associated liver fibrosis.

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central regulator of this multi-organ syndrome. Why was this review needed? Current CKM management focuses on treating individual organs rather than the underlying disease network. Growing evidence suggests that gut dysbiosis and reduced butyrate production may drive inflammation, insulin resistance, and cardiorenal dysfunction, creating new opportunities for microbiota-targeted therapy. What did the review show? • Loss of butyrate-producing bacteria is consistently associated with CKM syndrome. • Butyrate improves insulin sensitivity and reduces chronic metabolic inflammation. • It protects against oxidative stress, endothelial dysfunction, and excessive RAAS activation. • Butyrate helps maintain intestinal barrier integrity and restores gut microbial balance. • Dietary fiber, direct butyrate supplementation, and microbiota-directed therapies all show potential to increase butyrate availability. • The authors propose a novel gut–butyrate–CKM axis, positioning butyrate as a key mediator linking gut health with cardiovascular, renal, and metabolic function. Clinical Impact: This review shifts the focus from treating individual CKM components to targeting a common upstream mechanism. Microbiota-based interventions that restore butyrate production may become valuable adjuncts in preventing and managing CKM syndrome. Take-Home Message: Butyrate is emerging as a central molecular link between gut health and cardiovascular, kidney, and metabolic diseases. Restoring butyrate-producing bacteria through diet or microbiota-targeted therapies may represent a promising new strategy for integrated CKM management.

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have prognostic value in SIA. • The analysis included 691 patients with available biomarker data and was independently validated in a separate multicenter cohort. • CK20 positivity was associated with significantly better overall survival. • CDX2 positivity was also associated with improved survival, consistent with findings previously reported in colorectal and gastric cancers. • In contrast, CK7 positivity identified a higher-risk subgroup with more aggressive clinical features. • CK7-positive tumors were more likely to be: Proximally located Advanced stage at diagnosis Microsatellite stable • Loss of CK20 expression and loss of CDX2 expression were independent predictors of worse survival, even after adjustment for stage, treatment, age, sex, and tumor location. • Combined CK7, CK20, and CDX2 expression profiles identified distinct prognostic categories with substantially different outcomes. • Importantly, these markers are already widely available in routine pathology practice and require no additional molecular testing. • The study demonstrates that immunohistochemistry can provide both diagnostic and prognostic information in SIA. • The findings support incorporation of these markers into routine pathological reporting for small intestinal adenocarcinoma. • Risk stratification based on CK7, CK20, and CDX2 may eventually help guide surveillance intensity, clinical trial enrollment, and treatment decision-making. • Given the rarity of SIA, easily obtainable biomarkers are particularly valuable because large molecular datasets remain limited. Bottom line: CK20 and CDX2 positivity identify favorable-prognosis small intestinal adenocarcinoma, whereas CK7 positivity marks a clinically important higher-risk subgroup. Routine assessment of these inexpensive immunohistochemical markers may significantly improve prognostic stratification in this rare malignancy.

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging evidence suggests that metabolic communication between the liver and other organs may also play a critical role in glucose homeostasis. Problem Statement: While excessive hepatic gluconeogenesis is a well-established contributor to hyperglycemia, the mechanisms by which fatty liver influences distant metabolic tissues remain incompletely understood. Identifying novel liver-derived signals that disrupt glucose regulation could reveal new therapeutic targets for diabetes and metabolic liver disease. Summary: This study uncovers a previously unrecognized liver–gut communication pathway through which fatty liver promotes hyperglycemia. The investigators demonstrate that hepatocytes release alkaline phosphatase (ALP), which acts remotely on intestinal stem cells and alters their differentiation program. Mechanistically, ALP activates a signaling cascade involving α2δ-1, calcium channel translocation, and calcineurin–NFATC2 signaling, ultimately suppressing SOX21 expression. Reduced SOX21 activity lowers BMP7 production and impairs differentiation of intestinal stem cells into enteroendocrine L-cells. As a result, production of glucose-lowering gut hormones is diminished, contributing to worsening hyperglycemia. Importantly, this mechanism operates independently of increased hepatic glucose production, revealing an entirely new pathway linking fatty liver to systemic glucose dysregulation. Therapeutically, inhibition of hepatic ALP synthesis improved glycemic control and enhanced the glucose-lowering effects of metformin, suggesting potential clinical relevance. These findings redefine the role of the liver in metabolic regulation by demonstrating that fatty liver can directly influence intestinal stem cell fate and endocrine function through endocrine-like signalling. Beyond advancing understanding of MASLD-associated diabetes, the study identifies the ALP–SOX21 axis as a promising therapeutic target. Overall, this work provides compelling evidence that liver–gut communication is a fundamental regulator of blood glucose homeostasis and opens new avenues for treating metabolic disease by targeting inter-organ signalling pathways rather than hepatic metabolism alone.

Neural Remodeling Drives Early Pancreatic Carcinogenesis : Gastroenterology | Jul 2026

Introduction: Pancreatic ductal adenocarcinoma (PDAC) develops through a series of precursor lesions, beginning with acinar-to-ductal metaplasia (ADM) and progressing to pancreatic intraepithelial neoplasia and invasive cancer. While genetic alterations such as KRAS mutations are established drivers of this process, the contribution of the neural microenvironment to early pancreatic carcinogenesis remains poorly understood. Problem Statement: Neural remodeling is increasingly recognized as an important component of the pancreatic tumor microenvironment, yet the mechanisms linking nerve growth and epithelial transformation during the earliest stages of PDAC development are unclear. Understanding these interactions may reveal opportunities to intercept pancreatic cancer before invasive disease develops. Summary: This study identifies a previously unrecognized bidirectional communication network between pancreatic epithelial cells and neural elements that promotes pancreatic carcinogenesis. The investigators demonstrated that inflammation and oncogenic KRAS-driven ADM actively stimulate neurite outgrowth, while neural remodeling in turn facilitates metaplastic transformation and disease progression. Central to this interaction is ganglioside-mediated signaling, particularly involving the metabolite GM3, which serves as a key molecular mediator of neural-acinar crosstalk. Through comprehensive lipidomic, transcriptomic, and functional analyses, the authors identified β-1,4-galactosyltransferase 5 as a critical regulator of ganglioside biosynthesis that is progressively overexpressed across ADM, pancreatic intraepithelial neoplasia, and PDAC lesions in both murine and human tissues. Functional studies confirmed that this enzyme plays an essential role in initiating metaplastic changes and driving progression toward invasive pancreatic cancer. Importantly, pharmacologic inhibition of β-1,4-galactosyltransferase 5 suppressed neuronal growth, disrupted the neural-metaplastic niche, and attenuated ADM formation and progression. These findings establish neural remodeling as an active participant rather than a passive bystander in pancreatic carcinogenesis. The study provides compelling evidence that ganglioside-driven neural-epithelial interactions create a permissive microenvironment for tumor initiation and progression. By identifying glycosphingolipid metabolism and neuronal–ADM signaling as actionable targets, this work opens new avenues for early intervention strategies aimed at preventing the development of pancreatic cancer at its premalignant stages.

Engineered CAR-T Cells Boost STING Therapy in Pancreatic Cancer : Gastroenterology | Jul 2026

Introduction: Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies but has achieved limited success in solid tumors such as pancreatic cancer. Major barriers include T-cell exhaustion, poor persistence within tumors, and a profoundly immunosuppressive tumor microenvironment. Novel approaches that enhance CAR-T cell activity while simultaneously remodeling the tumor microenvironment are urgently needed. Problem Statement: STING agonists can stimulate antitumor immunity and inflame the tumor microenvironment, making them attractive partners for CAR-T therapy. However, activation of STING signaling within T cells themselves may impair CAR-T cell function, potentially limiting the effectiveness of this combination strategy. Understanding how to exploit STING activation while avoiding its detrimental effects on T cells is critical for advancing cellular therapies in pancreatic cancer. Summary: This study demonstrates a novel strategy to enhance CAR-T cell therapy in pancreatic cancer by genetically eliminating STING signaling within CAR-T cells while simultaneously administering a STING agonist. The combination resulted in superior tumor cell killing, increased CAR-T cell proliferation, reduced T-cell exhaustion, and expansion of long-lived effector-memory T cells. Mechanistic analyses revealed that the therapeutic benefit depended on preserving STING activation within cancer cells while preventing STING-mediated dysfunction in CAR-T cells. The investigators identified a positive feedback loop involving interferon-γ and tumor necrosis factor released by CAR-T cells, which enhanced tumor-cell STING signaling and further strengthened antitumor immune responses. This reciprocal interaction improved CAR-T cell fitness and amplified tumor destruction. In both xenograft and syngeneic pancreatic cancer models, STING-deficient CAR-T cells combined with the STING agonist diABZI achieved superior tumor control compared with either strategy alone. Enhanced efficacy was accompanied by increased intratumoral CAR-T cell accumulation and favorable remodeling of the tumor microenvironment. These findings provide compelling preclinical evidence that selective manipulation of STING signaling can overcome key obstacles limiting CAR-T therapy in solid tumors. The study introduces a potentially transformative strategy for pancreatic cancer and suggests that engineering CAR-T cells to resist intrinsic STING activation may unlock the full therapeutic potential of STING agonists in immune-resistant malignancies.

Adipose Tissue: Nature Reviews Endocrinology | June 2026

• Adipose tissue is no longer viewed simply as a fat storage organ; it is now recognized as a highly active endocrine and neuro-regulatory organ that coordinates whole-body metabolism. • Adipose tissue communicates through two major pathways: Humoral signaling (hormones, metabolites, lipid mediators, cytokines, extracellular vesicles) Neuronal signaling (sympathetic and sensory nerve networks) • Adipose-derived humoral factors include: Adipokines Lipid mediators Metabolites Chemokines Exosomal microRNAs • These signals regulate insulin sensitivity, glucose metabolism, lipid utilization, inflammation, vascular health, and overall cardiometabolic homeostasis. • Sympathetic nerves provide rapid control of adipose tissue function, stimulating: Lipolysis in white adipose tissue Thermogenesis in brown adipose tissue Browning of white adipose tissue • Sensory nerve fibers act as metabolic sensors, detecting chemical, thermal, and mechanical signals within adipose tissue and relaying information back to the central nervous system. • This bidirectional communication creates a sophisticated feedback system linking adipose tissue to the brain and peripheral organs. • Cold exposure activates thermogenic adipose tissue and induces release of specific adipokines and lipid mediators that improve systemic glucose and lipid metabolism. • Exercise also modifies adipose signaling networks, contributing to many of the metabolic benefits traditionally attributed solely to skeletal muscle. • Obesity disrupts both endocrine and neural communication within adipose tissue, resulting in: Adipokine dysregulation Chronic inflammation Insulin resistance Adipose neuropathy • Similar disturbances are observed in: Type 2 diabetes Lipodystrophy Aging-related metabolic disorders • Age-related deterioration of adipose signaling may contribute to declining metabolic flexibility and increased cardiometabolic risk. • Emerging technologies are rapidly transforming adipose tissue research, including: Single-cell sequencing Multi-omics platforms Secretome profiling Organoid models Optogenetics Click chemistry • These tools are enabling unprecedented characterization of adipose-derived signaling molecules and neural circuits. • Future therapeutic opportunities may include: Synthetic adipokine analogues Lipid mediator–based therapies Neural circuit modulation Precision targeting of adipose communication pathways • The review places adipose tissue at the center of modern metabolic medicine, linking obesity, diabetes, cardiovascular disease, aging, and energy homeostasis through integrated endocrine and neural networks. Bottom line: Adipose tissue functions as a sophisticated humoral–neuronal communication hub that actively regulates systemic metabolism. Understanding and manipulating these signaling networks may open new therapeutic avenues for obesity, diabetes, cardiometabolic disease, and healthy aging.

ANGPTL3 Inhibitors Deliver Broad Lipid Lowering : Eur J Prev Cardiol | June 2026

Introduction: Despite major advances in lipid-lowering therapy, many patients continue to experience residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins and mixed dyslipidemia. Angiopoietin-like protein 3 (ANGPTL3) has emerged as an attractive therapeutic target because of its central role in regulating lipid metabolism. Genetic studies have shown that reduced ANGPTL3 activity is associated with favorable lipid profiles and lower cardiovascular risk, prompting the development of several ANGPTL3-targeted therapies. Problem Statement: Although monoclonal antibodies, antisense oligonucleotides, and small interfering RNA therapies targeting ANGPTL3 have demonstrated promising lipid-lowering effects in individual clinical trials, the overall metabolic impact of this therapeutic class has not been comprehensively evaluated. Clarifying their efficacy across multiple lipid parameters is essential for understanding their potential role in cardiovascular risk reduction. Summary: This meta-analysis of randomized controlled trials provides a comprehensive assessment of the metabolic effects of ANGPTL3 inhibition. The analysis demonstrated that ANGPTL3-targeted therapies produce substantial reductions across a broad range of atherogenic lipoproteins, with particularly pronounced effects on triglyceride-rich lipoproteins. Significant improvements were observed in triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, remnant cholesterol, and total cholesterol. Modest reductions were also noted in lipoprotein(a), an increasingly recognized cardiovascular risk factor. Importantly, ANGPTL3 inhibition achieved marked suppression of circulating ANGPTL3 levels, confirming effective target engagement. Differences among therapeutic approaches were observed, with the monoclonal antibody evinacumab demonstrating stronger reductions in several cholesterol-related parameters, while small interfering RNA agents showed particularly favorable effects on triglyceride-rich lipoproteins. Notably, no meaningful impact on systemic inflammatory markers was identified, suggesting that the benefits of ANGPTL3 inhibition are primarily mediated through lipid modification rather than anti-inflammatory mechanisms. These findings position ANGPTL3 inhibition as a promising strategy for patients with persistent dyslipidemia and residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins. Future outcome-driven studies will be essential to determine whether these impressive lipid improvements translate into meaningful reductions in cardiovascular events and long-term clinical benefit.